[HTML][HTML] Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
Background The impact of dupilumab, an anti–interleukin (IL) 4 receptor α antibody that
inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD)
is unknown. Objectives To assess T-cell–dependent and T-cell–independent humoral
immune responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab
efficacy and safety. Methods In a randomized, double-blinded, placebo-controlled study …
inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD)
is unknown. Objectives To assess T-cell–dependent and T-cell–independent humoral
immune responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab
efficacy and safety. Methods In a randomized, double-blinded, placebo-controlled study …
